Dr Lalchandani Labs Ltd Stock Price Today (NSE: DLCL)
Fundamental Score
Dr Lalchandani Labs Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Dr Lalchandani Labs Ltd share price today is ₹7.17, down 4.91% on NSE/BSE as of 7 August 2026. Dr Lalchandani Labs Ltd (DLCL) is a Small-cap company in the Healthcare Service Provider sector with a market capitalisation of ₹7.16 (Cr). The 52-week high for DLCL share price is ₹28.70 and the 52-week low is ₹6.46. At a P/E ratio of 119.40x, DLCL is currently trading above its industry average P/E of 42.23x. The company has a Return on Equity (ROE) of 0.50% and a debt-to-equity ratio of 0.15.
Dr Lalchandani Labs Ltd Share Price Chart — NSE/BSE Historical Performance
Dr Lalchandani Labs Ltd share price chart: 1.17% return over the past month. 52-week high ₹28.70, 52-week low ₹6.46.
Dr Lalchandani Labs Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹7.32 | ₹7.43 | ₹7.31 | ₹7.31 | 92.00K (Cr) | |
| ₹7.39 | ₹7.88 | ₹7.39 | ₹7.69 | 88.00K (Cr) | |
| ₹7.38 | ₹7.98 | ₹7.38 | ₹7.77 | 24.00K (Cr) | |
| ₹7.77 | ₹7.77 | ₹7.33 | ₹7.76 | 16.00K (Cr) | |
| ₹7.42 | ₹7.42 | ₹7.41 | ₹7.41 | 16.00K (Cr) | |
| ₹7.79 | ₹7.79 | ₹7.79 | ₹7.79 | 0.00 (Cr) | |
| ₹8.20 | ₹8.20 | ₹7.58 | ₹7.79 | 48.00K (Cr) | |
| ₹7.56 | ₹7.97 | ₹7.56 | ₹7.97 | 28.00K (Cr) | |
| ₹7.95 | ₹7.95 | ₹7.95 | ₹7.95 | 0.00 (Cr) | |
| ₹7.92 | ₹7.92 | ₹7.92 | ₹7.92 | 0.00 (Cr) |
Dr Lalchandani Labs Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹7.39 | ₹7.88 | ₹7.31 | ₹7.31 | -1.08% | |
| ₹7.68 | ₹8.49 | ₹7.33 | ₹7.77 | +1.17% | |
| ₹9.50 | ₹10.14 | ₹6.46 | ₹7.42 | -21.89% | |
| ₹10.75 | ₹10.83 | ₹8.87 | ₹9.99 | -7.07% | |
| ₹14.07 | ₹14.07 | ₹9.15 | ₹10.34 | -26.51% | |
| ₹15.09 | ₹16.67 | ₹14.34 | ₹14.81 | -1.86% | |
| ₹17.25 | ₹17.99 | ₹15.88 | ₹15.88 | -7.94% | |
| ₹19.77 | ₹23.69 | ₹15.19 | ₹17.58 | -11.08% | |
| ₹19.22 | ₹21.90 | ₹15.39 | ₹20.81 | +8.27% | |
| ₹22.41 | ₹22.41 | ₹20.23 | ₹20.23 | -9.73% | |
| ₹21.58 | ₹23.60 | ₹20.51 | ₹23.58 | +9.27% | |
| ₹26.25 | ₹28.70 | ₹21.86 | ₹22.71 | -13.49% |
AI Research Briefing
Powered by Gemini · 2026-04-10
Micro-cap diagnostic firm with negative growth and declining promoter holding is a value trap, not a turnaround story.
WHAT'S HAPPENING NOW (last 2-4 weeks)
Dr. Lalchandani Labs approved the basis of allotment under its rights issue on March 3, 2026. The company also extended the closing date of the rights issue to February 27, 2026, to facilitate better participation from shareholders.
CORE STORY (THE REAL GAME)
Retail investors are betting on a turnaround story in a micro-cap diagnostic chain, fueled by hopes of increased healthcare spending and digitization in the Indian healthcare sector. The market is likely pricing in an aggressive expansion story.
- Rights issue completion adds to share supply, diluting value.
- Declining promoter holding signals lack of confidence.
- Poor sales growth and low ROE raise concerns about long-term viability.
- Significant order wins with clear revenue impact.
- Successful integration of new technologies or services.
- Turnaround in sales growth and profitability.
- Micro/SME cap: Illiquidity risk is high.
- Negative Sales CAGR 5Y: -6.11%
- Promoter Holding decreased by 26.03%
Promoter holding decreased by 26.03%.
Healthcare sector in India is growing, but DLCL's small size makes it vulnerable.
No major news found after live search.
Profit not converting to cash; Free Cash Flow 5Y: ₹0.55 Cr.
Near-term survival depends on successful execution of rights issue and cost-cutting measures. Long-term viability questionable without significant revenue growth.
Primary Thesis Risk
Inability to generate sustainable revenue growth will lead to collapse.
For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Dr Lalchandani Labs Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Dr Lalchandani Labs Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of DLCL across key market metrics for learning purposes.
Positive Indicators
3 factors identified
Conservative Debt Levels (D/E: 0.15)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (6.00x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
9 factors identified
Below-Average Return on Equity (0.50%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (0.79%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Premium Valuation Risk (P/E: 119.40x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
Profit Decline Concern (-148.15%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes.
Revenue Contraction (-8.58%)
Observation: Sales decline may indicate market challenges or competitive pressures.
Analysis: Negative revenue growth requires analysis of market conditions.
Limited Growth History (-15.59% CAGR)
Observation: Below-average 5-year sales growth trajectory.
Analysis: Low sales CAGR may indicate mature markets or limited growth opportunities.
Weak Earnings Growth (-43.06% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation.
Stagnant Profit Growth (-43.15% CAGR)
Observation: Limited 5-year profit growth trajectory.
Analysis: Low profit growth may indicate scalability challenges or market maturity.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Dr Lalchandani Labs Ltd vs Healthcare Service Provider Peers
Peer Comparison - Healthcare Service Provider
Compare Dr Lalchandani Labs Ltd with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Dr Lalchandani Labs LtdDr Lalchandani ...Selected✓ DLCL • 541299 | 3.8/100 | ₹7.17₹7 | ₹7.16₹7.16 | 119.40Average 119.4 Average | 0.50%Poor 0.50% Poor | 0.79%Poor 0.79% Poor | 0.15Excellent 0.1 Excellent | -43.15%Poor -43.15% Poor | -15.59%Poor -15.59% Poor | 0.00% |
Dr Lal PathLabs LtdDr Lal PathLabs... LALPATHLAB • 539524 | 57.7/100 | ₹1905.20₹1905 | ₹28908.91₹28908.91 | 55.39Average 55.4 Average | 22.30%Excellent 22.30% Excellent | 28.00%Excellent 28.00% Excellent | 0.08Excellent 0.1 Excellent | 12.33%Good 12.33% Good | 11.81%Good 11.81% Good | 0.81% |
Vijaya Diagnostic Centre LtdVijaya Diagnost... VIJAYA • 543350 | 67.8/100 | ₹1344.40₹1344 | ₹14307.85₹14307.85 | 82.71Average 82.7 Average | 19.74%Good 19.74% Good | 21.29%Excellent 21.29% Excellent | 0.44Excellent 0.4 Excellent | 15.47%Excellent 15.47% Excellent | 16.66%Excellent 16.66% Excellent | 0.14% |
Metropolis Healthcare LtdMetropolis Heal... METROPOLIS • 542650 | 57.9/100 | ₹582.45₹582 | ₹11858.49₹11858.49 | 60.38Average 60.4 Average | 13.81%Average 13.81% Average | 17.77%Good 17.77% Good | 0.15Excellent 0.1 Excellent | 1.46%Average 1.46% Average | 10.52%Good 10.52% Good | 0.35% |
Thyrocare Technologies LtdThyrocare Techn... THYROCARE • 539871 | 46.7/100 | ₹579.00₹579 | ₹8420.27₹8420.27 | 52.36Average 52.4 Average | 28.40%Excellent 28.40% Excellent | 35.38%Excellent 35.38% Excellent | 0.09Excellent 0.1 Excellent | 8.37%Good 8.37% Good | 10.88%Good 10.88% Good | 1.76% |
Krsnaa Diagnostics LtdKrsnaa Diagnost... KRSNAA • 543328 | 31.9/100 | ₹527.45₹527 | ₹1777.47₹1777.47 | 17.31Average 17.3 Average | 10.89%Average 10.89% Average | 12.70%Average 12.70% Average | 0.54Good 0.5 Good | -11.13%Poor -11.13% Poor | 11.75%Good 11.75% Good | 0.50% |
Suraksha Diagnostic LtdSuraksha Diagno... SURAKSHA • 544293 | 56.2/100 | ₹252.15₹252 | ₹1359.30₹1359.30 | 42.23Average 42.2 Average | 14.12%Average 14.12% Average | 16.97%Good 16.97% Good | 0.53Good 0.5 Good | 31.68%Excellent 31.68% Excellent | 17.26%Excellent 17.26% Excellent | 0.00% |
One Global Service Provider IncOne Global Serv... ONEGLOBAL • 514330 | 82.2/100 | ₹564.95₹565 | ₹1178.25₹1178.25 | 16.95Average 16.9 Average | 65.27%Excellent 65.27% Excellent | 87.02%Excellent 87.02% Excellent | 0.00Excellent 0.0 Excellent | 97.21%Excellent 97.21% Excellent | 167.02%Excellent 167.02% Excellent | 0.00% |
3B Blackbio Diagnostics Ltd3B Blackbio Dia... 3BBLACKBIO • 532067 | 60.3/100 | ₹1248.10₹1248 | ₹1079.13₹1079.13 | 18.42Average 18.4 Average | 19.77%Good 19.77% Good | 25.48%Excellent 25.48% Excellent | 0.01Excellent 0.0 Excellent | -12.44%Poor -12.44% Poor | -8.95%Poor -8.95% Poor | 0.31% |
Sastasundar Ventures LtdSastasundar Ven... SASTASUNDR • 533259 | 39/100 | ₹301.45₹301 | ₹1035.54₹1035.54 | 539.34Average 539.3 Average | 0.29%Poor 0.29% Poor | -0.05%Poor -0.05% Poor | 0.04Excellent 0.0 Excellent | 16.91%Excellent 16.91% Excellent | 19.09%Excellent 19.09% Excellent | 0.00% |
49.4/100 | ₹239.10₹239 | ₹600.78₹600.78 | 20.55Average 20.6 Average | 19.92%Good 19.92% Good | 23.27%Excellent 23.27% Excellent | 0.31Excellent 0.3 Excellent | — — | — — | 0.00% | |
Top Healthcare Service Provider Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Dr Lal PathLabs Ltd share price28908.91 Cr
- Vijaya Diagnostic Centre Ltd share price14307.85 Cr
- Metropolis Healthcare Ltd share price11858.49 Cr
- Thyrocare Technologies Ltd share price8420.27 Cr
- Krsnaa Diagnostics Ltd share price1777.47 Cr
Dr Lalchandani Labs Ltd PE Ratio History
Historical price-to-earnings ratio for DLCL — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2024 | ₹1.43 | ₹16.90 | 11.8x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Dr Lalchandani Labs Ltd Quarterly Performance
Latest quarterly metrics for DLCL — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
-8.58%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
-148.15%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
-15.59%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
-43.15%
Compounded annual net profit growth over 5 years
Dr Lalchandani Labs Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for DLCL — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Dr Lalchandani Labs Ltd Financial Statements
Annual income statement, balance sheet and cash flow for Dr Lalchandani Labs Ltd (DLCL) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Dr Lalchandani Labs Ltd
About DLCL (Dr Lalchandani Labs Ltd)
Dr Lalchandani Labs Ltd is a renowned healthcare service provider at the forefront of diagnostics and preventative health in India. With a legacy built on accuracy and patient-cent...ric care, DLCL offers a comprehensive suite of services designed to cater to diverse healthcare needs. The labs function as critical hubs for precision medicine, delivering high-quality pathology testing alongside cutting-edge imaging modalities. DLCL empowers patients and medical professionals with vital information to facilitate timely diagnoses, informed treatment decisions, and proactive wellness management. The company remains steadfast in its mission to elevate the standards of diagnostic care across the country. DLCL distinguishes itself through its integrated approach to healthcare, providing a seamless experience for patients and partners alike. Beyond routine testing, DLCL offers a range of specialized services, including advanced molecular diagnostics, comprehensive health check packages, and expert consultations. Strategic partnerships with hospitals and corporations further extend DLCL's reach, enabling the delivery of on-site lab management and customized health solutions. Through a combination of skilled professionals, state-of-the-art technology, and unwavering commitment to quality, DLCL continuously strives to meet the evolving demands of the Indian healthcare landscape. Embracing innovation and accessibility, Dr Lalchandani Labs Ltd extends its services beyond traditional brick-and-mortar locations. Their robust online platform offers convenient access to test bookings, report delivery, and personalized health insights. By leveraging technology, DLCL aims to democratize healthcare and empower individuals to take control of their well-being. With a focus on continuous improvement and a deep understanding of the unique needs of the Indian population, Dr Lalchandani Labs Ltd stands as a trusted partner in promoting health and well-being across communities.
Company Details
Key Leadership
Latest News
DLCL Share Price: Frequently Asked Questions
What is the current share price of Dr Lalchandani Labs Ltd?
Dr Lalchandani Labs Ltd (DLCL) trades at ₹7.17 on NSE and BSE. Market cap ₹7.16 (Cr). Educational data only.
What is the P/E ratio of Dr Lalchandani Labs Ltd?
Dr Lalchandani Labs Ltd has a P/E of 119.40x vs industry average 42.23x.
What is the Bull Run score for Dr Lalchandani Labs Ltd?
Dr Lalchandani Labs Ltd has a Bull Run score of 3.8/100 based on 25+ financial parameters.
Does Dr Lalchandani Labs Ltd pay dividends?
Dr Lalchandani Labs Ltd has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of Dr Lalchandani Labs Ltd?
Dr Lalchandani Labs Ltd has ROE of 0.50%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Dr Lalchandani Labs Ltd?
Dr Lalchandani Labs Ltd has debt-to-equity of 0.15.
Is Dr Lalchandani Labs Ltd a good investment?
Bull Run gives Dr Lalchandani Labs Ltd a score of 3.8/100. This is not investment advice — consult a SEBI-registered advisor.